
Opinion|Videos|May 7, 2024
Evaluating the Impact of Metastatic Breast Cancer on Patients
An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement















































































































































































































